Shares of Novartis AG (NYSE:NVS) have been given a consensus recommendation of “Hold” by the eighteen brokerages that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $83.19.

A number of analysts have recently issued reports on NVS shares. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price objective on the stock in a report on Tuesday, September 19th. Cowen set a $90.00 target price on shares of Novartis and gave the stock a “hold” rating in a report on Wednesday, August 9th. BidaskClub upgraded shares of Novartis from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Leerink Swann boosted their target price on shares of Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis in a report on Tuesday, October 24th.

Several institutional investors have recently made changes to their positions in NVS. City Holding Co. boosted its holdings in shares of Novartis by 4.6% during the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after buying an additional 54 shares in the last quarter. WFG Advisors LP grew its position in shares of Novartis by 38.1% during the second quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in shares of Novartis during the third quarter worth about $106,000. Cable Hill Partners LLC grew its position in shares of Novartis by 588.8% during the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after purchasing an additional 1,107 shares in the last quarter. Finally, Harding Loevner LP purchased a new stake in shares of Novartis during the second quarter worth about $146,000. 10.87% of the stock is owned by institutional investors.

Shares of Novartis (NVS) traded up $0.25 on Friday, reaching $86.05. 1,178,747 shares of the company’s stock were exchanged, compared to its average volume of 2,291,198. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. Novartis has a 1 year low of $66.93 and a 1 year high of $86.90. The company has a market capitalization of $224,480.00, a price-to-earnings ratio of 17.97, a P/E/G ratio of 2.72 and a beta of 0.72.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.04. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. During the same quarter in the previous year, the firm posted $1.23 earnings per share. The business’s revenue was up 2.4% on a year-over-year basis. research analysts forecast that Novartis will post 4.75 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Novartis AG (NVS) Given Consensus Rating of “Hold” by Analysts” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/01/novartis-ag-nvs-given-consensus-rating-of-hold-by-analysts.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.